title: [Efficacy and Safety of Rosuvastatin in Patients of Different Risk Groups of Developing Cardiovascular].
abstract: The purpose of the review - analysis of randomized clinical trials to evaluate the efficacy and safety of rosuvastatin in respect of primary and secondary prevention of cardiovascular events, as well as in patients with acute coronary syndrome. As a primary pathogenetic therapy aimed at reducing the risk of cardiovascular disease and death from cardiovascular disease ischemic nature, used statins, which have both lipid-lowering and pleiotropic other positive properties. When analyzing the results of the comparative evaluation of different statins best performance indicators in primary and secondary prevention of cardiovascular events were at the rosuvastatin. The first drug is bioequivalent to the original rosuvastatin in Russia became mertenil company "Gedeon Richter". The therapeutic equivalence of mertenil is comparable with that of the original drug in patients of different groups at risk of developing cardiovascular complications (from low to very high). Mertenil can be regarded as an effective and safe drug from the group of statins for primary and secondary prevention of cardiovascular complications in patients of all risk groups.
authors.affiliation: I.M. Sechenov First Moscow Medical State University, 8, build. 2, Trubetskaya str., 119992 Moscow, Russia.
authors.forename: O M
authors.initials: OM
authors.lastname: Drapkina
authors.affiliation: I.M. Sechenov First Moscow Medical State University, 8, build. 2, Trubetskaya str., 119992 Moscow, Russia.
authors.forename: S O
authors.initials: SO
authors.lastname: Eliashevich